China’s speed in generating first-in-human data has catalyzed a race across the globe to reshape regulatory requirements to compete. BioCentury’s analysts, along with special guests Detlev Mennerich, head of Boehringer Ingelheim Venture Fund, and Mehdi Ainouche, partner at Jeito Capital, discussed where Europe fits in that landscape and other takeaways from the 26th annual Bio€quity Europe conference in Prague. This special episode of BioCentury This Week has been brought to you by Jeito Capital.
00:01 - Sponsor Message: Jeito Capital 03:14 - China’s Speed Challenge 04:08 - Europe’s Clinical Trial Opportunity 11:48 - Speed vs. Capital Efficiency 15:52 - Takeaways from Richard Pazdur 19:58 - FDA Uncertainty and Global Alternatives 26:50 - Biopharma M&A Outlook 33:34 - The Next Wave of Science
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Podden och tillhörande omslagsbild på den här sidan tillhör
BioCentury. Innehållet i podden är skapat av BioCentury och inte av,
eller tillsammans med, Poddtoppen.
